257 related articles for article (PubMed ID: 33626896)
1. Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin B; Hu C; Korn EL
Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
[TBL] [Abstract][Full Text] [Related]
2. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
3. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
4. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
5. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
6. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
7. Noninferiority trials with nonadherence to the assigned randomized treatment.
Korn EL; Gray RJ; Freidlin B
Clin Trials; 2019 Dec; 16(6):673-681. PubMed ID: 31409130
[TBL] [Abstract][Full Text] [Related]
8. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
9. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
10. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
[TBL] [Abstract][Full Text] [Related]
11. Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio.
Hida E; Tango T
Pharm Stat; 2018 Sep; 17(5):489-503. PubMed ID: 29984524
[TBL] [Abstract][Full Text] [Related]
12. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
13. Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials.
Abulizi X; Flandre P
J Clin Epidemiol; 2018 Apr; 96():63-72. PubMed ID: 29289760
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial design for assessing noninferiority when superiority is expected.
Freidlin B; Korn EL; George SL; Gray R
J Clin Oncol; 2007 Nov; 25(31):5019-23. PubMed ID: 17971602
[TBL] [Abstract][Full Text] [Related]
15. A comparative study to alternatives to the log-rank test.
Dormuth I; Liu T; Xu J; Pauly M; Ditzhaus M
Contemp Clin Trials; 2023 May; 128():107165. PubMed ID: 36972865
[TBL] [Abstract][Full Text] [Related]
16. Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks.
Han D; Chen Z; Hou Y
J Biopharm Stat; 2018; 28(4):797-807. PubMed ID: 29157093
[TBL] [Abstract][Full Text] [Related]
17. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
19. On sample size calculation for comparing survival curves under general hypothesis testing.
Jung SH; Chow SC
J Biopharm Stat; 2012; 22(3):485-95. PubMed ID: 22416836
[TBL] [Abstract][Full Text] [Related]
20. Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time.
Phadnis MA; Mayo MS
J Appl Stat; 2021; 48(6):1009-1032. PubMed ID: 35707732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
